Clinical Scorecard: Primary Glioblastoma Presenting as Brain Metastasis in a Patient with ALK-Positive Lung Adenocarcinoma: A Case Study and Review of the Literature
At a Glance
Category
Detail
Condition
Primary Glioblastoma
Key Mechanisms
Metachronous double primary cancers (DPCs) in the context of ALK-positive lung adenocarcinoma.
Target Population
Patients with ALK-positive lung adenocarcinoma and new intracranial lesions.
Care Setting
Oncology and neurology clinics.
Key Highlights
New intracranial lesions in lung cancer patients may indicate a second primary cancer.
Differentiation between brain metastasis and primary brain tumors is challenging.
Timely pathological confirmation can reduce diagnostic delays.
ALK-positive lung cancer patients are at high risk for brain metastases.
The patient developed glioblastoma two years post lung cancer surgery.
Guideline-Based Recommendations
Diagnosis
Consider second primary cancers in patients with new intracranial lesions.
Management
Use targeted therapy and local radiotherapy based on accurate diagnosis.
Monitoring & Follow-up
Regular follow-up imaging for early detection of new lesions.
Risks
Misdiagnosis can lead to inappropriate treatment and poor outcomes.
Patient & Prescribing Data
ALK-positive lung adenocarcinoma patients.
Initial treatment with ensartinib followed by lorlatinib after misdiagnosis.
Clinical Best Practices
Maintain a high index of suspicion for second primary cancers.
Conduct multidisciplinary reviews for complex cases.
Ensure timely imaging and pathological evaluations.
